Sotorasib (Lumakras,Sotoldx)

Sotorasib covalently binds to the switch pocket of KRAS G12C mutant protein, specifically inhibits GTPase activity and blocks abnormal RAS signaling.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Sotorasib Drug News

FDA Approves Sotorasib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

On May 28, 2021, Amgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved sotorasib for the treatment of adult pat···【More】
Update: 29 Apr,2026Source: BigbearViews: 124
FDA Approves Sotorasib in Combination with Panitumumab for the Treatment of Metastatic Colorectal Cancer with KRAS G12C Mutation

On January 17, 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Lumakras (sotorasib) in combination with Vectibix (···【More】
Update: 27 Apr,2026Source: BigbearViews: 124
The FDA has approved sotorarazib (Lumakras) in combination with panitumumab

Here is the professional, accurate English translation of the full text, formatted for medical/pharmaceutical documentation:On May 28, 2021, Amgen ann···【More】
Update: 04 Mar,2026Source: BigbearViews: 119
The FDA has approved sotorarazib (Lumakras) in combination with panitumumab

On January 17, 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the combination of sottorazib (Lumakras) and panitu···【More】
Update: 04 Mar,2026Source: BigbearViews: 114